The safety evaluation of adjuvants during vaccine development: The AS04 experience

Vaccine

Volumn 29, Issue 27, 2011, Pages 4453-4459

  Garçon, Nathalie ^a   Segal, Lawrence ^a   Tavares, Fernanda ^a   Van Mechelen, Marcelle ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; Immunoenhancer; Safety; Vaccine

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM SALT; AS 04; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; IMMUNOENHANCER; IMMUNOSTIMULATING AGENT; LIPOPOLYSACCHARIDE; PLACEBO; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ARTHRALGIA; AUTOIMMUNE DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DRUG DESIGN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; HEMODIALYSIS; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; KIDNEY FAILURE; MYALGIA; NONHUMAN; PAIN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN REDNESS; SWELLING; SYMPTOM; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALUMINUM HYDROXIDE; ANIMALS; AUTOIMMUNE DISEASES; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LIPID A; MALE; MICE; MIDDLE AGED; RABBITS; VIRAL VACCINES; YOUNG ADULT;

EID: 79958173060     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.046     Document Type: Review

References (58)

1. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5:505-517.
2. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
3. Brennan F.R., Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 2005, 23:3210-3222.
4. European Medicines Agency: Committee for proprietary medicinal products (CPMP). Note for guidance on preclinical pharmacological and toxicological testing of vaccines; 1997. Report no.: CPMP/SWP/465/95. Available from: http://www.ema.europa.eu/pdfs/human/swp/046595en.pdf.
5. Food and Drug Administration (FDA): Center for Biologics Evaluation and Research (CBER). Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies; 1997. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM175909.pdf.
6. World Health Organisation. WHO guidelines on nonclinical evaluation of vaccines; 2003. Available from: http://www.who.int/biologicals/publications/nonclinical_evaluation_vaccines_nov_2003.pdf.
7. European Medicines Agency: Committee for medicinal products for human use (CHMP). Guideline on adjuvants in vaccines for human use; 2004. Report no.: EMEA/CHMP/VEG/134716. Available from: http://www.ema.europa.eu/pdfs/human/vwp/13471604en.pdf.
8. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol Rev 2009, 227:248-263.
9. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835.
10. Jorgensen T.N., Gubbels M.R., Kotzin B.L. New insights into disease pathogenesis from mouse lupus genetics. Curr Opin Immunol 2004, 16:787-793.
11. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
12. Finkelman F.D. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007, 120:506-515. quiz 16-7.
13. Choubey D., Panchanathan R. Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol Lett 2008, 119:32-41.
14. Wraith D.C., Goldman M., Lambert P.H. Vaccination and autoimmune disease: what is the evidence?. Lancet 2003, 362:1659-1666.
15. Dietert R.R., Dietert J.M., Gavalchin J. Risk of autoimmune disease: challenges for immunotoxicity testing. Immunotoxicity testing: methods and protocols. Methods in Molecular Biology 2010, Humana Press. R.R. Dietert (Ed.).
16. International Conference on Harmonisation (ICH). General considerations for clinical trials; 1997. Report no.: E8. Available from: http://www.ich.org/LOB/media/MEDIA484.pdf.
17. Garçon N. Preclinical development of AS04. In: Davies G, editor. Vaccine adjuvants. 2010/01/26 ed. Clifton, N.J.: Springer Science+Business Media; 2010. p. 15-27.
18. Brewer J.M. (How) do aluminium adjuvants work?. Immunol Lett 2006, 102:10-15.
19. Qureshi N., Takayama K., Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982, 257:11808-11815.
20. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008, 65:3231-3240.
21. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signalling in C3H/HeJ and C57BL/10ScCr mice: mutations in tlr4 gene. Science 1998, 282:2085-2088.
22. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
23. Food and Drug Administration: Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications; 2006. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm092267.pdf.
24. Garçon N., Van Mechelen M., Wettendorff M. Development of AS04, a novel and improved adjuvant system containing MPL and aluminium salt. Immunopotentiators in modern vaccines 2006, 161-177. Elsevier Academic Press, London. 1st ed. V. Schijns, D. O'Hagan (Eds.).
25. Segal L., Wilby O.K., Willoughby C.R., Veenstra S., Deschamps M. Evaluation of the intramuscular administration of Cervarix™ vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol. 2011, 31:111-120.
26. Baldrick P., Richardson D., Elliott G., Wheeler A.W. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol 2002, 35:398-413.
27. Toyoda Y. Mutagenicity study (AMES test) of toothpaste ingredients. Soc Cosmet Chem (Japan) 1985, 19:100-104.
28. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82:497-505.
29. Davidson A., Aranow C. Lupus nephritis: lessons from murine models. Nat Rev Rheumatol 2010, 6:13-20.
30. Chiorini J.A., Cihakova D., Ouellette C.E., Caturegli P. Sjögren syndrome: advances in the pathogenesis from animal models. J Autoimmun 2009, 33:190-196.
31. Ahlqvist E., Hultqvist M., Holmdahl R. The value of animal models in predicting genetic susceptibility to complex diseases such as rheumatoid arthritis. Arthritis Res Ther 2009, 11:226-235.
32. Vallabhapurapu S., Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009, 27:693-733.
33. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
34. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008, 8:594-606.
35. Pascual V., Farkas L., Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006, 18:676-682.
36. Bourke E., Bosisio D., Golay J., Polentarutti N., Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003, 102:956-963.
37. Ruprecht C.R., Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naïve B cells. Eur J Immunol 2006, 36:810-816.
38. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202.
39. Caron G., Duluc D., Frémaux I., Jeannin P., David C., Gascan H., et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells. J Immunol 2005, 175:1551-1557.
40. Komai-Koma M., Jones L., Ogg G.S., Xu D., Liew F.Y. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A 2004, 101:3029-3034.
41. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
42. Verstraeten T., Descamps D., David M.P., Zahaf T., Hardt K., Izurieta P., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008, 26:6630-6638.
43. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008, 8:235-247.
44. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer Vaccines in healthy women aged 18-45 years. Hum Vaccines 2009, 5:705-719.
45. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255.
46. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
47. Romanowski B., Colares de Borba P., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
48. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008, 4:425-434.
49. Kong N.C., Beran J., Kee S.A., Miguel J.L., Sánchez C., Bayas J.M., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68:2298-2303.
50. Bernstein D.I., Aoki F.Y., Tyring S.K., Stanberry L.R., St-Pierre C., Shafran S.D., et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005, 40:1271-1281.
51. Leroux-Rouls G., Moreaux E., Desombre I. Immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy 1994, 205.
52. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347:1652-1661.
53. National Institute of Allergy and Infectious Diseases. Study Finds Genital Herpes Vaccine Ineffective in Women; 2010. Available from: http://www.niaid.nih.gov/news/newsreleases/2010/Pages/Herpevac.aspx.
54. Cooper G.S., Stroehla B.C. The epidemiology of autoimmune diseases. Autoimmun Rev 2003, 2:119-125.
55. Siegrist C.A., Lewis E.M., Eskola J., Evans S.J., Black S.B. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007, 26:979-984.
56. Medicines and Healthcare products Regulatory Agency. MHRA Public Assessment Report, October 2010: Cervarix (HPV vaccine): Update on UK safety covering the first two years of the HPV immunisation programme; 2010. Available from: http://www.mhra.gov.uk/.
57. UK Commission on Human Medicine. Human papilloma virus (HPV) vaccine-2-year safety review. In the summary report based on the minutes of the meeting of the pharmacovigilance expert advisory group held on 15th September 2010; 2010. Available from: http://www.mhra.gov.uk/home/groups/l-cs-el/documents/committeedocument/con096942.pdf.
58. Food and Drug Administration: Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials; 2007. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.